The estimated Net Worth of Hazel M Aker is at least $195 Thousand dollars as of 21 July 2020. Hazel Aker owns over 41,972 units of Oncternal Therapeutics stock worth over $195,231 and over the last 5 years Hazel sold ONCT stock worth over $0.
Hazel has made over 1 trades of the Oncternal Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Hazel bought 41,972 units of ONCT stock worth $99,893 on 21 July 2020.
The largest trade Hazel's ever made was buying 41,972 units of Oncternal Therapeutics stock on 21 July 2020 worth over $99,893. On average, Hazel trades about 10,493 units every 0 days since 2019. As of 21 July 2020 Hazel still owns at least 46,987 units of Oncternal Therapeutics stock.
You can see the complete history of Hazel Aker stock trades at the bottom of the page.
Hazel's mailing address filed with the SEC is 12230 EL CAMINO REAL, SUITE 300, , SAN DIEGO, CA, 92130.
Over the last 5 years, insiders at Oncternal Therapeutics have traded over $26,287 worth of Oncternal Therapeutics stock and bought 1,526,610 units worth $3,062,129 . The most active insiders traders include Pharmaceutical (Usa) Inc.Sh..., Charles Theuer, and Robert James Wills. On average, Oncternal Therapeutics executives and independent directors trade stock every 68 days with the average trade being worth of $302,970. The most recent stock trade was executed by Robert James Wills on 8 April 2024, trading 3,086 units of ONCT stock currently worth $27,651.
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting receptor-tyrosine kinase-like Orphan Receptor 1. The company is headquartered in San Diego, California.
Oncternal Therapeutics executives and other stock owners filed with the SEC include: